United States: Patent-Eligibility Of hESC Challenged

Now that the U.S. Supreme Court has determined that isolated, naturally-occurring genes are not patent-eligible (see, Ass'n. for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __ (2013))("Myriad"), Consumer Watchdog ("CW", formerly known as The Foundation for Taxpayer and Consumer Rights, a self-described public charity dedicated to provide a voice for taxpayers and consumers) has asked the Federal Circuit to apply the holding of Myriad to in vitro cultured, human embryonic stem cell cultures and deem them patent-ineligible for failing to satisfy 35 U.S.C. § 101. Consumer Watchdog v. Wisconsin Alumni Research Foundation, No. 13-1377 (Fed. Cir. 2013).

Reexamination of U.S. Patent No. 7,029,913

CW's challenge is contained in an appeal from a Decision of the USPTO's Board of Patent Appeals ("Board") in inter partes reexamination No. 95/000,154, which confirmed the patentability of claims 1-3 of U.S. Patent No. 7,029,913 (the '913 Patent) entitled "Primate Embryonic Stem Cells". The '913 Patent issued on April 18, 2006 naming Dr. James A. Thomson of the University of Wisconsin as the sole inventor. The '913 Patent is assigned to Appellee Wisconsin Alumni Research Foundation ("WARF").

In the reexamination proceeding itself, Appellant CW only challenged the novelty and non-obviousness of the claims. The Board determined that the claims were novel because the cited prior art neither disclosed nor enabled using feeder cells to isolate human embryonic stem cells ("hESCs"). The Board also determined that the evidence of record supported a finding of non-obviousness because one of skill in the art would not have known how to identify and select hESCs during the stem cell derivation process.

After reexamination, claim 1 of the '913 Patent, the broadest and only independent claim recites:

1. A replicating in vitro cell culture of pluripotent human embryonic stem cells derived from a pre-implantation embryo, wherein the stem cells (i) will proliferate in an in vitro culture for over one year in an undifferentiated state without the application of exogenous leukemia inhibitory factor, (ii) maintain a karyotype in which the chromosomes are euploid through prolonged culture, (iii) maintain the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, (iv) are inhibited from differentiation when cultured on a fibroblast feeder layer.

Patent-Eligibility of hESCs

CW did not challenge the patent-eligibility of in vitro cultured hESCs in the reexamination proceeding but raises this argument for the first time in this appeal. CW argues that patent-eligibility is a threshold issue to be addressed before subordinate questions such as those related to anticipation and obviousness, citing Alexsam, Inc. v. IDT Corp., 2013 U.S. App. LEXIS 10009, at 30 (Fed. Cir. May 20, 2013)(Mayer, J. dissenting) and U.S. Nat'l Bank v. Indep. Ins. Agents, 508 U.S. 439, 447 (1993). Thus, CW argues that raising the issue of patent-eligibility at this stage is appropriate.

Although the '913 Patent expressly recites that the claimed hESCs are an in vitro culture, CW argues that the express limitation of the claims "merely identify properties that are inherent in all ES cells, including those that exist naturally." CW Brief at page 15. CW opines that, "if the claimed ES cells were not the same as natural ES cells, the claimed invention would offer very little benefit for medical research." Id. CW also argues that similar to the facts of Myriad, the '913 Patent claims recite neither a method of preparation nor a scientific application of the claimed composition, and that therefore, the claims are directed to a patent-ineligible product of nature. CW further contends that the '913 Patent claims do not distinguish the claimed hESCs from those that exist in nature and that the patentee "did not create or alter the properties inherent in stem cells any more than Myriad created or altered the genetic information encoded in the DNA it claimed." Id.

Anticipation and Obviousness

CW also challenges the Board's determination that the '913 Patent claims at issue were novel under 35 U.S.C. § 102. In the proceeding below, the Board held that the cited prior art (U.S. Patent No. 5,166,065, issued November 24, 1992 "Williams") did not teach the use of feeder cells to isolate embryonic stem cells. CW disagreed with the Board's interpretation that Williams only taught the use of feeder cells to maintain ES cells, but not to derive them.

CW also argues that no innovation was required to isolate the hESCs and that therefore, the claims are invalid for failing to satisfy 35 U.S.C. § 103 (non-obviousness). In arguing obviousness of the claims, CW challenges the expert opinion of Dr. Steward who declared that the morphology of hESCs are different from prior art mouse ES cell colonies. In the reexamination proceeding, Dr. Stewart had submitted a declaration noting that hESCs colonies are flatter and more compact than mouse ES cell colonies and that therefore, colonies of hESCs had not been described before the invention of the '913 Patent. CW urges the Federal Circuit not to rely on the testimony of Dr. Stewart but rather to rely on the teachings of other cited prior art that describes the isolation of mouse embryonic stem cells to guide the ordinary skilled scientist to test different colony types for features common to embryonic stem cells.

CW also urges the Federal Circuit to disregard secondary evidence of non-obviousness presented in the reexamination proceeding. In particular, CW asks the Federal Circuit to disregard evidence that others in the field had followed inventor Thomson's work to isolate hESCs and to disregard the acclaim Dr. Thomson has received in the field for his patented invention.

Cultured hESCs - Nonnatural Composition of Matter?

In its recent Myriad decision, the US Supreme Court held that isolated, naturally-occurring genes are not patent-eligible under 35 U.S.C. § 101 because isolated genes are a product of nature. The Myriad Court distinguished the facts and holding from a prior Supreme Court's decision, Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). In Chakrabarty, the Supreme Court had previously held that genetically modified bacterium was patent-eligible. The Myriad Court distinguished the claimed isolated, natural-occurring genes from the subject of the Chakrabarty case, wherein the Court had held that the inventors had created a patentable, new composition of matter when they added four plasmids to a bacterium, which enabled it to break down various components of crude oil. Myriad, Slip Op. at 12, citing Chakrabarty, 447 U. S. at 305, and n. 1. The Myriad Court explained that the claimed genetically modified bacterium was "not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter—a product of human ingenuity 'having a distinctive name, character [and] use.'" Id., citing Chakrabarty, at 309–310. The Chakrabarty bacterium was new "with markedly different characteristics from any found in nature," 447 U. S., at 310, due to the additional plasmids and resultant "capacity for degrading oil." Id., citing Chakrabarty, at 305, n. 1. The Court in Myriad held that in contrast, "Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention." Myriad, Slip Op. at 12. The Court in Myriad also determined, however, that unlike isolated, naturally-occurring genes, man-made cDNA was patent-eligible because "the lab technician unquestionably creates something new when cDNA is made." Myriad, Slip Op. at 17.

Thus, the question for the Federal Circuit in this case is whether the claimed, cultured hESCs are markedly different from naturally-occurring hESCs. Does the process of culturing the cells provide the cells with "with markedly different characteristics from any found in nature?" Or, put differently, are hESCs more like patent-eligible man-made genes or more like patent-ineligible isolated, naturally-occurring genes?

Many in the biotech community were relieved that the Supreme Court in Myriad limited its holding of patent-ineligibility to isolated, naturally-occurring genes. However, patent practitioners cautioned that Myriad's holding could potentially be applied to other isolated, naturally-occurring products, including stem cells. The WARF case is likely the first test case before the Federal Circuit, and perhaps the U.S. Supreme Court ultimately, to define the reach and impact of Myriad beyond gene patents.

A copy of CW's Brief is attached. Appellee WARF's brief is due August 15, 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.